Further work to reconcile these observations is needed to (1) better understand mechanisms of CDK4/6i-induced tumor regression and (2) design rational combinations comprising CDK4/6 inhibitors and BH3 mimetics. The gene discussed is CDK4; the disease is neoplasm.